Innovation  Saving  Lives

The Latest from OBD

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications

Hunter, E., et. al.,
medRxiv

December 27, 2021

https://www.medrxiv.org/content/10.1101/2021.12.21.21268094v1

Development and validation of blood-based prognostic biomarkers for severity of COVID disease outcome using EpiSwitch 3D genomic regulatory immuno-genetic profiling

Hunter, E. et. al.,
medRxiv

June 28, 2021

https://doi.org/10.1101/2021.06.21.21259145

Genomic Architecture Differences at the HTT Locus Associated with Symptomatic and Pre-Symptomatic Cases of Huntington’s Disease in a Pilot Study

Salter, et. al.,
Psychiatry Open Access

March 31, 2021

https://doi.org/10.33805/2638-8073.131

3D genomic capture of regulatory immuno-genetic profiles in COVID-19 patients for prognosis of severe COVID disease outcome

Hunter, E., et. al.,
bioRxiv

March 17, 2021

https://doi.org/10.1101/2021.03.14.435295

Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups.

Alshaker, H., et. al.,
J Transl Med 19, 46 (2021)

February 2, 2021

https://doi.org/10.1186/s12967-021-02710-y

A conversation about Systemic Sclerosis

Akoulitchev, et. al.,
European Biopharmaceutical Review

October 17, 2020

http://www.samedanltd.com/magazine/12/issue/327/article/5365

The Prospective Study of Epigenetic Regulatory Profiles in Sport and Exercise Monitored Through Chromosome Conformation Signatures

Hall, ECR., et. al.,
Genes 2020, 11(8), 905

August 7, 2020

https://doi.org/10.3390/genes11080905

Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies

Hunter, E., et. al.,
Translational Medicine Communications (2020) 5:5

March 25, 2020

https://doi.org/10.1186/s41231-020-00054-1

Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch® epigenetic profiling

Hunter, E., et. al.,
SITC, J. Immunotherapy Cancer 7, 282 (2019) P143.

November 8, 2019

https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P143_multitherapy.pdf

Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch® epigenetic profiling

Hunter, E., et. al.,
SITC, J. Immunotherapy Cancer 7, 282 (2019) P142.

November 8, 2019

https://www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P142_avelumab.pdf